Recent News

• 02.27.2025 - The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
• 02.24.2025 - Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
• 02.20.2025 - Lexaria’s Strategic Business Pursuit of DehydraTECH-Liraglutide
• 02.11.2025 - Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
• 02.06.2025 - Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
• 02.06.2025 - Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
• 02.05.2025 - Lexaria Updates its Ongoing Human Study GLP-1-H24-4
• 02.05.2025 - Lexaria Updates its Ongoing Human Study GLP-1-H24-4
• 02.05.2025 - Lexaria Updates its Ongoing Human Study GLP-1-H24-4
• 01.30.2025 - Lexaria Releases Annual Letter from the CEO

Recent Filings

• 02.05.2025 - 8-K Current report
• 02.05.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 01.30.2025 - EFFECT Notice of Effectiveness
• 01.22.2025 - S-3 Registration statement under Securities Act of 1933
• 01.16.2025 - 3 Initial statement of beneficial ownership of securities
• 01.15.2025 - 8-K Current report